• Non ci sono risultati.

Alarming use of chelation therapy

N/A
N/A
Protected

Academic year: 2021

Condividi "Alarming use of chelation therapy"

Copied!
1
0
0

Testo completo

(1)

Acta of the International Symposia on Metal Complexes – ISMEC Acta, Volume 4 - ISMEC 2014, June 8th – 12th 2014 – Pavia (Italy)

45

Alarming use of chelation therapy.

Guido CRISPONI, a) Valeria M. NURCHI, a) Joanna I. LACHOWICZ, a) Miriam

CRESPO-ALONSO, a) M. Antonietta ZORODDU, b) Massimiliano PEANA b)

a)

Dipartimento di Scienze Chimiche e Geologiche, University of Cagliari, Cittadella

Universitaria, 09042 Monserrato-Cagliari, Italy, b) Dipartimento di Chimica e Farmacia,

University of Sassari, Via Vienna 2, 07100, Sassari, Italy; crisponi@unica.it

Chelation therapy is a consolidated medical procedure used primarily to hinder the effects of toxic metal ions on human tissues [1]. Its application spans a broad spectrum of disorders, ranging from acute metal intoxication to genetic metal-overload. The use of chelating agents is compromised by a number of serious side effects, mainly attributable to perturbed equilibrium of essential metal ion homeostasis and dislocation of complexed metal ions to dangerous body sites. For this reason, chelation therapy has been limited to specific critical and otherwise untreatable conditions and needs to be monitored within an appropriate clinical context [2-3]. An alarming issue today is that fraudsters use the term “chelation therapy” to take advantage of and make profit from people with tragic health problems. We believe that scientists working in this field have the corollary obligation to deter these frauds and to inform the scientific community of the possible side effects and complications of chelation therapy. This duty is all the more important if we consider the detrimental and even life threatening consequences that can occur in subjects with no clear clinical and laboratory evidence of metal intoxication. The aim of this communication is to present how this “false chelation therapy” developed and in which diseases it is currently applied [4].

References:

[1] Crisponi, G.; Nurchi, V. M.; Crespo-Alonso, M.; Toso, L., Chelating Agents for Metal Intoxication. Current Medicinal Chemistry 2012, 19, 2794-2815.

[2] Crisponi, G.; Nurchi, V. M.; Fanni, D.; Gerosa, C.; Nemolato, S.; Faa, G., Copper-related diseases: from chemistry to molecular pathology. Coord. Chem. Rev. 2010, 254, 876-889.

[3] Crisponi, G.; Remelli, M., Iron chelating agents for the treatment of iron overload.

Coord. Chem. Rev. 2008, 252, 1225-1240.

[4] Crisponi, G.; Nurchi, V. M.; Lachowicz, I. J.; Crespo-Alonso,.M; Zoroddu, M. A.; Peana, M., Kill or Cure: Misuse of chelation therapy for human diseases. Coord. Chem.

Rev. 2014, accepted for publication.

Riferimenti

Documenti correlati

The clustering of the 16S rDNA restriction profiles on the mixed bacterial popula- tions allowed discriminating every sample as unique and, in particular, to assess sample

Observed corrosion rates of Cu and Cu-based alloys at all test sites Measured average annual corrosion rates for Cu sheet and the three copper-based alloys (Cu4Sn, Cu15Zn and

Children aged between 1 and 4 years, who had historically been affected by varicella diseases and were enrolled in the current uni- versal programme of varicella vaccination

prevailing conditions under which polymer, solvent and surface interact. The adsorption of ions and molecules to polymer surfaces plays a role in many applications

This is also testified in Figure 37, where the numerical simulation (S2) takes now account of both effects. A relatively small difference between model S1 and S2 can be observed.

Once the existence of (at least some of) the characteristics of neoliberalism have been ascertained through the ideal types mentioned above, a better definition

To investigate the effect of adding specific amount of CeO 2 on the catalytic activity, the X-ray diffraction, SEM-EDX, laser particle size distribution and BET

Le CBT, espresse in percentuali, dei 4 batteri parodontopatoge- ni trovati con il test molecolare, a cinque mesi da pre-SM sono diminuite del 64%, a 12 mesi del 35% per il gruppo B..